NO20064868L - materiale for nevrogenisk smerteregulering - Google Patents

materiale for nevrogenisk smerteregulering

Info

Publication number
NO20064868L
NO20064868L NO20064868A NO20064868A NO20064868L NO 20064868 L NO20064868 L NO 20064868L NO 20064868 A NO20064868 A NO 20064868A NO 20064868 A NO20064868 A NO 20064868A NO 20064868 L NO20064868 L NO 20064868L
Authority
NO
Norway
Prior art keywords
pain control
neurogenic pain
neurogenic
control
salts
Prior art date
Application number
NO20064868A
Other languages
English (en)
Inventor
Norimasa Kanamitsu
Masakazu Yoshimura
Yutaka Itsuji
Takashi Osaki
Motoko Kawashima
Original Assignee
Maruishi Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharma filed Critical Maruishi Pharma
Publication of NO20064868L publication Critical patent/NO20064868L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/64—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Det beskrives et farmasøytisk materiale for å regulere nevropatisk smerte, hvor materialet omfatter en forbindelse som vist i formel: Eller salter derav.
NO20064868A 2004-05-24 2006-10-25 materiale for nevrogenisk smerteregulering NO20064868L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004153206 2004-05-24
PCT/JP2005/009361 WO2005113501A1 (ja) 2004-05-24 2005-05-23 神経因性疼痛制御剤組成物

Publications (1)

Publication Number Publication Date
NO20064868L true NO20064868L (no) 2007-02-26

Family

ID=35428364

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064868A NO20064868L (no) 2004-05-24 2006-10-25 materiale for nevrogenisk smerteregulering

Country Status (14)

Country Link
US (1) US20080021042A1 (no)
EP (1) EP1749817A4 (no)
JP (1) JPWO2005113501A1 (no)
CN (1) CN1956955A (no)
AU (1) AU2005245292A1 (no)
BR (1) BRPI0511546A (no)
CA (1) CA2563968A1 (no)
EC (1) ECSP067107A (no)
IL (1) IL178814A0 (no)
MX (1) MXPA06013766A (no)
NO (1) NO20064868L (no)
RU (1) RU2006145875A (no)
TW (1) TW200602318A (no)
WO (1) WO2005113501A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048332A1 (ja) * 2002-11-26 2004-06-10 Maruishi Pharmaceutical Co., Ltd. イソインドリン誘導体
US20090291983A1 (en) * 2006-07-12 2009-11-26 Astrazeneca Ab 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents
CN104803905B (zh) * 2015-04-17 2017-10-10 复旦大学 一种合成异吲哚啉‑1‑酮衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2117740B1 (no) * 1970-12-14 1974-04-12 Rhone Poulenc Sa
WO1984003089A1 (fr) * 1983-02-05 1984-08-16 Takeda Chemical Industries Ltd Derives condenses de pyrrolinone
EP0091241B1 (en) * 1982-04-02 1988-12-28 Takeda Chemical Industries, Ltd. Condensed pyrrolinone derivatives, and their production
JP2002512633A (ja) * 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
WO2004048332A1 (ja) * 2002-11-26 2004-06-10 Maruishi Pharmaceutical Co., Ltd. イソインドリン誘導体

Also Published As

Publication number Publication date
RU2006145875A (ru) 2008-06-27
WO2005113501A1 (ja) 2005-12-01
AU2005245292A1 (en) 2005-12-01
CN1956955A (zh) 2007-05-02
MXPA06013766A (es) 2007-02-08
JPWO2005113501A1 (ja) 2008-03-27
CA2563968A1 (en) 2005-12-01
ECSP067107A (es) 2007-02-28
US20080021042A1 (en) 2008-01-24
EP1749817A1 (en) 2007-02-07
IL178814A0 (en) 2007-03-08
TW200602318A (en) 2006-01-16
EP1749817A4 (en) 2007-12-26
BRPI0511546A (pt) 2008-01-02

Similar Documents

Publication Publication Date Title
WO2008126665A3 (en) Isoxazoline compounds and their use in pest control
TWI256390B (en) Nitrogenous heterocyclic compound and pharmaceuticals thereof
NO20171775A1 (no) Ftalazinonderivat
WO2009041705A3 (en) 5-membered heterocyclic compounds as proton pump inhibitors
DK1649760T3 (da) Sammensætning, som indeholder equol-producerende mælkesyrebakterie
WO2008153154A1 (ja) 環状化合物、フォトレジスト基材及びフォトレジスト組成物
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
TW200730486A (en) Organic sulfur compounds and use thereof
TW200744588A (en) Pharmaceutical composition for external use
DK1558579T3 (da) N-alkyl-4-methylenamino-3-hydroxy-2-pyridoner som antimikrobialer
DK2114933T3 (da) Piperidin-GPCR-agonister
EA200801959A1 (ru) Высокоразветвленный полипропилен
NO20084583L (no) Makrosykliske kinase-inhibitorer
NO20035730L (no) Substituerte 1-oksa-2,8-diaza-spiro[4,5]dec-2-en-derivater som legemidler mot smerte
DK1608309T3 (da) 10,10-Dialkylprostanoidsyrederivater som midler til reduktion af det intraokulare tryk
ATE344055T1 (de) Zusammensetzungen für die elektroporation
WO2008136385A1 (ja) アミド化合物およびその用途
WO2009022327A3 (en) Novel process for preparing highly pure levocetirizine and salts thereof
WO2006024412A3 (en) Optically active phthalamides
NO20053715D0 (no) 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk
NO20064868L (no) materiale for nevrogenisk smerteregulering
NO20082369L (no) Nye vinyloge syrederivater
AR065597A1 (es) Compuesto ester y su uso
WO2009075250A1 (ja) 植物病害防除剤
WO2007007207A8 (en) Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application